Adamas Pharmaceuticals Inc (ADMS) is Reiterated by Mizuho to Buy, Raises Price Target to $ 26

Adamas Pharmaceuticals Inc (ADMS) was Reiterated by Mizuho to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 26 from a previous price target of $22 . Mizuho advised their investors in a research report released on Sep 8, 2016.

Many Wall Street Analysts have commented on Adamas Pharmaceuticals Inc. Noble Financial Initiated Adamas Pharmaceuticals Inc on Jun 17, 2016 to “Buy”, Price Target of the shares are set at $25.Mizuho Upgraded Adamas Pharmaceuticals Inc on Jun 16, 2016 to ” Buy”, Price Target of the shares are set at $22.

Adamas Pharmaceuticals Inc opened for trading at $15.25 and hit $15.82 on the upside on Wednesday, eventually ending the session at $15.63, with a gain of 2.90% or 0.44 points. The heightened volatility saw the trading volume jump to 199,321 shares. Company has a market cap of $343 M.

In a different news, on Apr 20, 2016, Natalie Mcclure (SVP, Product Development) sold 36,000 shares at $18.50 per share price. According to the SEC, on Dec 9, 2015, Ivan M Lieberburg (director) sold 3,000 shares at $16.23 per share price. On Jun 17, 2015, Richard H Booth (director) sold 1,000 shares at $19.32 per share price, according to the Form-4 filing with the securities and exchange commission.

Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.

Adamas Pharmaceuticals Inc

Leave a Reply

Adamas Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Adamas Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.